FIELD : biotechnology.SUBSTANCE : invention relates to biotechnology, specifically to a method for producing genetically engineered T-cells for immunotherapy, and can be used in medicine.EFFECT : method enables producing pathologically targeted T-cells for immunotherapy, which can be provided by chimeric antigenic receptors aimed at an antigen marker which is common for pathological cells and for said T cells, where the genes coding said markers are inactivated in said T cells and avoid self-elimination of the targeted T cells in immunotherapy.42 cl, 17 dwg, 24 tbl, 3 ex